StreetAlpha.app
Home › Stocks › VTGN

Vistagen Therapeutics, Inc. (VTGN)

Healthcare
$0.19
▲ +2.01%
LAST CLOSE · NOV 17

Vistagen develops nasal spray medicine candidates for conditions such as social anxiety disorder and depression. It last closed at $0.19 on Nov 17, up 2.01% on the day. VTGN reports earnings on Thu, Feb 11, 2027.

AI Auto Pilots
Is VTGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.4M
+230.2% vs a year ago
Net income
−$58.9M
−2475.6% margin
EPS (diluted)
−$1.35
Operating margin
−2543.1%
−$60.6M operating income
Valuation
Market cap
$8.7M
46.2M shares
P/E
–
No P/E while losing money
Price to sales
3.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.9M
At Sep 30
Shareholder equity
$15.0M
Shares outstanding
46.2M
At Nov 10
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: $1.1M$1.1MFY2022FY2023: −$227K−$227KFY2023FY2024: $1.1M$1.1MFY2024FY2025: $486K$486KFY2025FY2026: $1.3M$1.3MFY2026

From VTGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$0.36
$500,000 revenue est.
Year-ago EPS
-$0.45
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

VTGN · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 123% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the 20 day average at $0.18, and the nearest resistance the swing high (Nov 4) at $0.19.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 8.6%/day
Key levels
$5.1452 week high+2605.3%
$0.42200 day average+121.1%
$0.24100 day average+26.3%
$0.2250 day average+15.8%
$0.19Pivot R1+0.0%
$0.19Pivot+0.0%
$0.19Swing high (Nov 4)+0.0%
$0.19Last close
$0.1820 day average−5.3%
$0.18Pivot S1−5.3%
$0.17Swing low (Oct 30)−10.5%
$0.1652 week low−15.8%
Indicators
RSI (14)47.73Middle of its rangeNeutral
MACD-0.01Below its signal lineBearish
Stochastic75.9Middle of its rangeNeutral
ADX (14)10.1No clear trend
Williams %R-13.9Oversold below −80, overbought above −20Overbought
CCI (20)84.1Oversold below −100, overbought above 100Neutral
Rate of change+11.9%Change over 10 sessionsBullish
ATR (14)$0.02Typical daily range, 8.6% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for VTGN

What happened before

See how VTGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VTGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VTGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VTGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

VTGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼17 buying vs 22 selling
  • ▼Held by funds -2.9 pts
  • ▼Funds holding -7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4249−14.3%
In funds' top 1000–
Held by funds22.6%25.5%−2.9 pts
New / increased5 / 1210 / 15−32.0%
Reduced / sold out10 / 1214 / 16−26.7%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VTGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VTGN is in one of them and how their past VTGN trades turned out.

VTGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VTGN in an article yet. Here's the latest on the wider market.

About Vistagen Therapeutics

Vistagen is a pharmaceutical company based in South San Francisco, California, that is developing medicines for conditions including social anxiety disorder, depression, menopausal hot flashes, and cancer cachexia. Its candidates are nasal sprays designed to act on nerve receptors in the nose, with the aim of working without being absorbed into the bloodstream. The company has no approved products yet, and its candidates are being tested in clinical trials with patients.

Headquarters
South San Francisco, CA